without the exposure of the peritoneum to hypertonic glucose solutions. Background. The sustained ultrafiltration achieved by icodextrin is more suited for the daytime dwell in Key words: automated peritoneal dialysis; dialysis automated peritoneal dialysis (APD) than glucose adequacy; icodextrin; ultrafiltration solutions. Methods. Seventeen patients receiving APD underwent assessment using three different solutions for the daytime dwell: 2.27% glucose, 3.86% glucose and 7.5%
Icodextrin in automated peritoneal dialysis 1531 D/P creatinine (which were normally distributed) was per-
Methods and subjects
formed using the Pearson correlation coefficient and linear regression analysis was performed. Comparison of numbers We studied 17 patients (15 male and 2 female) receiving of patients with positive or negative daytime ultrafiltration APD with a daytime dwell. Patients with hypotension or with the three fluids was performed by the Chi squared test. tendency to dehydration which could possibly be exacerbated
The study was approved by the local research ethics by enhanced daytime ultrafiltration and patients with prob-committee and all patients gave written informed consent. lems due to raised intra-abdominal pressure (e.g. hernias and fluid leaks) were excluded. All other patients on APD were considered for entry into this study, without any selection related to clinical criteria or peritoneal membrane function. Results
Patients on APD not entering the study (15 patients) were excluded for the following reasons; absent daytime dwell (5 patients), intercurrent medical problems (4 patients-2 cere-Ultrafiltration brovascular disease, 1 recent myocardial infarction, 1 vascuThe median volume of dialysis fluid infused in during lar surgery), 3 patients declined, problems due to raised the daytime dwell was 1.5 (IQR 1.5-1.5) litres. The intra-abdominal pressure (2 patients) and poor compliance volumes drained after the daytime dwell were com-(1 patient). Median patient age was 48.5 years (range 26-69) and 2 had insulin-dependent diabetes mellitus. Causes of pared with the infused volume ( Table 1 ). The dialysate renal failure were glomerulonephritis (6 patients), chronic volume drained out after the daytime dwell was signipyelonephritis/vesicoureteric reflux (3 patients), diabetic ficantly lower for 2.27% glucose ( showed that the volumes for 3.86% glucose (P<0.01)
A total night-time exchange volume of 10-15 l was used (10 l and icodextrin (P<0.001) were greater than for 2.27% in 4 patients, 12.5 l in 1 patient and 15 l in 12 patients) with glucose, with no significant difference between 3.86% a median night-time dialysis time of 9 h (range 8.5-10.2 h).
Thus the median daytime dwell time was 15 h (range glucose and icodextrin. The resulting daytime ultrafil-13.8-15.5 h). Prior to the study the daytime exchange con-tration volumes were thus greater for 3.86% glucose sisted of 2.27% glucose in all patients with dialysate volumes (0.10 IQR 0.01 to 0.32 l ) P<0.01 and icodextrin (0.26 of 1.5 l in 14 patients and 2 l in 3 patients.
IQR 0.14 to 0.36 l ) P<0.001 than for 2.27% glucose The study comprised two phases. The first part of the (−0.19 IQR −0.54 to −0.08 l ) ( Table 1 ). The differstudy consisted of a comparison of 2.27% glucose, 3.86% ence between 3.86% glucose and icodextrin was not glucose and 7.5% icodextrin containing dialysis fluid for the statistically significant, but the sample size was not daytime dwell. Patients underwent assessment while per-adequate to confirm or exclude a significant difference For creatinine clearance the contribution of the daytime dwell was greater for 3.86% glucose (10.2 IQR 6.9 to 13.6 l/week/1.73 m2, P<0.02) and icodextrin (12.1 IQR 9.3 to 15.7 l/week/1.73 m2, P<0.0005) than for 2.27% glucose (8.8 IQR 4.9 to 11.9 l/week/1.73 m2). The daytime creatinine clearance was significantly greater for icodextrin than for 3.86% glucose (P<0.005). The total dialytic creatinine clearance was greater for icodextrin than 2.27% glucose and 3.86% glucose, with no difference between the two glucose solutions (Table 3) . icodextrin from 141.9 (2.4) mmol/l to 137.7 (2.4) mmol/l P <0.0001 Serum osmolality (measured directly) did not significantly change (317.7 s.d. 6.8 for regression analysis gave the relationship:
2.27% glucose and 315.9 s.d. 8.6 for icodextrin) and there were no associated symptoms. However, the UF (icodextrin)−UF(3.86% glucose) calculated osmolal gap increased from 5. 
Six month follow up on regular icodextrin
There was no significant change in peritoneal memTen patients continued on treatment with APD using brane function as estimated by a standard PET test icodextrin for the daytime dwell for a period of at least over the 6 month period in these subjects with 4 h 6 months (of the other 7 patients, 1 had received a dialysate plasma/creatinine ratio of 0.70 (s.d. 0.07) at renal transplant and one converted to haemodialysis the start of the study and 0.73 (s.d. 0.05) after 6 because of catheter problems before 6 months follow months. up and 5 had not been on treatment with icodextrin for 6 months at the time of completion of the study).
Discussion
The daytime ultrafiltration and contributions to weekly Kt/V and creatinine clearance were sustained over this 6 month period ( Table 4) . During this study, no It is well recognized that the daytime dialysate dwell makes an important contribution to total dialytic clearadverse effect of the use of icodextrin were noted. There was only a single episode of peritonitis (culture ance in APD and is essential in most patients (especially larger patients and those with little residual renal negative) responding to treatment with antibiotics (an incidence which would not be unexpected-at the time function) to enable currently recommended clearance targets to be achieved [3] . Glucose is currently the of analysis, the cumulative treatment time with icodextrin was equivalent to 72 patient months).
standard osmotic agent for peritoneal dialysis and the rapid ultrafiltration achieved over short time periods During the first month symptomatic hypotension occurred in 5 of 14 subjects to a degree requiring is ideally suited to the short night time cycles of APD.
However, glucose absorption over the long daytime reduction in number of antihypertensive agents or dosage. Despite this reduction in medication, there was dwell time in APD results in reduced effectiveness of moderately hypertonic solutions in achieving net a significant reduction in systolic blood pressure from Table 4 . Daytime ultrafiltration ( litres) and contribution of daytime dwell to weekly Kt/V (per week) and creatinine clearance ( l/week/1.73 m2)was maintained over a 6 month period (10 subjects) (values median and IQR) ultrafiltration at all from the daytime dwell, which ultrafiltration from the APD day dwell compared with our previously routine use of 2.27% glucose, resulting may have an adverse effect on patient fluid balance. This may be a particular problem in patients with high in a mean difference of 500 ml greater ultrafiltration volume per day. Icodextrin produced net fluid removal peritoneal membrane transport characteristics, who may have converted from CAPD to APD because of in all but one patient (and even in this single patient the drain volume was probably spurious as he has resulting ultrafiltration failure. The daytime dwell is also likely to contribute to the adverse effects of subsequently been demonstrated to reliably achieve positive ultrafiltration with icodextrin). The results glucose-based dialysis fluids, including hyperlipidaemia [5] , hyperglycaemia, hyperinsulinaemia and accumula-tended to be better than for 3.86% glucose but this was not statistically significant and a far larger study tion of body fat [6 ] . Glucose solutions also result in the formation of advanced glycosylation end-products (60-80 patients) would be required to confirm or exclude a significant difference of the magnitude (AGEs) which may have adverse effects relating to peritoneal structure and the development of vascular observed. However, the positive correlation of the difference in ultrafiltration between icodextrin and disease, and this may be a particular concern if using very hypertonic glucose solutions for the long daytime 3.86% glucose with the 4 h dialysate/plasma creatinine ratio suggests that icodextrin may at least be superior dwell [7] .
Icodextrin is a glucose polymer which has been in subjects with higher peritoneal membrane transport. It is also important that results with icodextrin are developed as an alternative osmotic agent for peritoneal dialysis [8] . It has been shown to produce gradual achieved without exposure of the patient or peritoneal membrane to glucose for a relatively long period of sustained ultrafiltration for the long overnight dwell period in CAPD (8-12 h duration) which is superior time, whereas it is necessary to use particularly hypertonic solutions to achieve comparable results with to weaker glucose solutions and at least as good as the most hypertonic glucose solutions [4] . It uniformly glucose. The increased drained dialysate volume achieved with icodextrin was shown to result in an achieves net fluid removal over these time periods in CAPD. Icodextrin, due to its high molecular weight enhanced total dialytic weekly creatinine clearance and Kt/V. and reflection coefficient, causes ultrafiltration by colloid osmosis, with passage of water through the small
The fall in serum sodium observed was asymptomatic and of the same magnitude as previously pore system, unlike glucose which is believed to act on ultra small transcellular pores [9-11]. Icodextrin has reported for both APD and CAPD [4, 17] . The increased osmolal gap was again compatible with accubeen shown to prolong technique survival for CAPD in patients with CAPD failure due to poor ultrafiltra-mulation of icodextrin metabolites of a similar degree to that previously observed in both APD and CAPD tion [12] and it may be effective in managing the temporary loss of ultrafiltration with glucose solutions [17] . It is a potential concern that accumulation of maltose and other metabolites from the longer daytime that may accompany peritonitis. Some icodextrin is absorbed and is metabolized to smaller oligosaccharide dwell in APD would be greater than from CAPD, but this does not seem to occur; possibly due to greater breakdown products, especially the disaccharide maltose [13] . This is usually metabolized to glucose by the clearance by the rapid nocturnal cycles [17] .
The longitudinal observations showed that the effects enzyme maltase which is present in the normal kidney and is absent in chronic renal failure. Thus there is a of icodextrin in APD are maintained over a 6 month period, without any reduction in ultrafiltration or degree of accumulation of these metabolites, reaching a steady state at 2 weeks, with removal by dialysis change in PET test results. The reduction in blood pressure and need for antihypertensive medication is during non-icodextrin exchanges. Increasing experience with icodextrin (up to 5 years in some CAPD patients) of great potential interest. Cardiovascular disease in a major cause of the increased mortality in ESCRF and has shown no adverse effects from this maltose accumulation, which rapidly reverses on stopping icodextrin blood pressure is likely to be an important factor in this [18] . Evidence in haemodialysis suggests that use [13] . Icodextrin is iso-osmolar and therefore may be more biocompatible than hypertonic glucose solu-hydration may play an important role in hypertension in dialysis patients and strict control of fluid status tions. Furthermore, in in-vitro studies icodextrin has been shown to result in a lower level of AGE produc-may result in control of blood pressure in haemodialysis with increased survival [19] . This area has not tion than glucose solutions [14] .
The ultrafiltration profile achieved with icodextrin been studied in great detail yet in peritoneal dialysis, but it is possible that control of fluid state may prove would be ideally suited to the long daytime dwell of APD. An initial study showed an effective ultrafiltra-to be as important a part of 'adequate dialysis' as small solute clearances [20] . The non-randomized tion with icodextrin with improved Kt/V during the daytime dwell in APD compared with a dry daytime nature of the follow up part of this study precludes useful analysis of longer term blood pressure data, peritoneal cavity [15] . A subsequent randomized prospective trial has shown enhanced ultrafiltration and where additional factors changing over time (such as diminishing residual renal function and alterations of clearance using icodextrin as the daytime dwell in APD compared with variable concentrations of glucose night-time cycles) are likely to obscure the effects of icodextrin in the small number of patients followed up (mean 2.25-2.41%) [16 ] .
This study shows that icodextrin achieves superior for 6 months. 
